| 摘要 |
The compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein it further relates to pharmaceutical compositions containing, and methods of using for the inhibition of phosphodiesterase (PDE) type IV or the production of tumor necrosis factor (TNF) in a mammal. Wherein; R is H, C1-9alkyl, -(CH2)m(5 to 10 membered heterocyclyl) wherein m is 0 to 2, (C1-6alkoxy)C1-8alkyl, C2-8alkenyl, or -(Z1)b(Z2)c(C8-10aryl) wherein b and c are independently 0 or 1, Z1 is C1-6alkylene or C2-6alkenylene, and Z2 is 0, S, SO2, or NR12, and wherein said R groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of halo, hydroxy, C1-5alkyl, C2-5alkenyl, C1-6alkoxy, trifluoromethyl, nitro, -CO2R12, -C(O)NR12R13, -NR12R13 and -SO2NR12R13; R1 is H, C1-9alkyl, C2-3alkenyl, or phenyl, wherein said alkyl, alkenyl and phenyl R, groups are optionally substituted by I to 3 substituents independently selected from the group consisting of methyl, ethyl, trifluoromethyl, and halo; R2 is R18, -C(O)NR12(CHR12)mC(O)NR12O(CH2)q(C8-10) aryl), -C(=NR32)NH(CH2)p(C8-10aryl), -C(O)NR12(CHR12)mC(O)NR12(CH2)pOR12, -C(O)NR12(CHR12)mS(C1-4alkyl), -C(=NOC(O)R25)R26, -CR17R18CHR20NR9SO2(CH2)pA, -CR17R18CHR28NR9P(O)(OR12)C(O)(C1-4alkyl), -CR17R18CHR26NR9P(O)(C1-4alkoxy)2, -Z3-R7, or -(CR17R18)mNR10(C(O))qR10 wherein p is 0 to 2, m is 1 to 6, and q is 1 or 2; or R2 is wherein in said formulas (la)-(li), the structures of formulas (If) and (Ig) are attached to formula I at carbons 5, 6, or 7 of said formulas (If) and (Ig), the dashed line in formulas (Ic) and (Id) indicates a single bond or double bond, except Re is absent in formulas (Ic) and (Id) where said dashed line indicates a double bond, n is 0 to 2, p is 0 to 6, and m is 0 or 1;
|
